DOT1L and breast carcinoma: In our cohort, DOT1L was also associated withER-α negativity (P=0.046,χ2-test), as well as progesterone receptornegativity (P=0.014, respectively,χ2-test) and triple-negative breast cancer(P=0.027, χ2-test), whichare aggressive breast cancer subtypes (Supplementary Table 1).